Senhwa Biosciences Signs AI-Driven Drug Development Partnership with CellType

Mar 5, 2026
Senhwa Biosciences has signed a strategic MOU with Y Combinator-backed biotech firm CellType to integrate AI into the development of its oncology drug CX-4945, aiming to expand its therapeutic potential and accelerate clinical progress.

Senhwa Biosciences has signed a major strategic Memorandum of Understanding with Y Combinator-backed biotech company CellType to advance the development of its oncology candidate Silmitasertib (CX-4945), announced in a press release.

The collaboration will integrate CellType’s AI platform to accelerate clinical development and global commercialization of CX-4945. The technology, originally developed at Yale University in collaboration with Google DeepMind, identified a new immune-modulatory mechanism for the compound. This research showed that CX-4945 may enhance immune activation, improve tumor antigen presentation, and convert non-responsive tumors into responsive ones.

Under the agreement, Senhwa and CellType will run a six-month pilot program focusing on indication expansion, biomarker discovery, and evaluation of combination therapies in immuno-oncology. The framework also includes plans to establish an AI-driven translational validation system.

CellType will use CX-4945 as a flagship case to demonstrate its AI platform’s capacity to reduce R&D risk and enhance therapeutic value. The partnership also leaves room for potential future collaborations, including joint ventures or co-development arrangements.

We hope you enjoyed this article

Free newsletter

Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

Guide
9 Voice to Text Apps

9 Voice to Text Apps

The best AI dictation apps for turning speech into clean text anywhere you type.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.